immune-complex membranoproliferative glomerulonephritis
Jan 26, 2026
ASPAVELI Fuels Sobi’s Growth Strategy in Europe for C3G and IC-MPGN
Summary Sobi has received European Commission approval for ASPAVELI (pegcetacoplan) to treat C3G and primary IC-MPGN, two rare, progressive kidney diseases. The approval follows a positive CHMP opinion (December 2025) and marks the first approved treatment for primary IC-MPGN and the first for both C3G...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
